MilliporeSigma
  • Inhibition of miR-217 Protects Against Myocardial Ischemia-Reperfusion Injury Through Inactivating NF-κB and MAPK Pathways.

Inhibition of miR-217 Protects Against Myocardial Ischemia-Reperfusion Injury Through Inactivating NF-κB and MAPK Pathways.

Cardiovascular engineering and technology (2020-01-10)
Yanfang Li, Liping Fei, Junli Wang, Qingying Niu
ABSTRACT

Recent studies have demonstrated that miRNAs play a vital role in regulating myocardial ischemia/reperfusion injury (MIRI). MiR-217 has been proven to be implicated in cardiac diseases such as chronic heart failure and cardiac myxoma. However, the role of miR-217 in MIRI is not clear. A mouse MIRI model was established and the myocardial infarct size was evaluated by TTC staining. The expression level of miR-217 in I/R group was determined by real-time polymerase chain reaction. Subsequently, MIRI mice and H9C2 cells were administrated with miR-217 inhibitor in vivo and in vitro, respectively. The levels of TNF-α and IL-6 were measured by commercially available ELISA kits. Blood and cell samples were collected for the measurement of lactate dehydrogenase (LDH) level and caspase-3 activity. Cell viability was assessed with the CCK-8 assay. We then explored the detailed molecular mechanisms by TargetScan 7.1 database and further studies were performed to prove the prediction by dual-luciferase reporter assay. Larger stainless infarct areas were observed in the MIRI group, accompanied by inceased serum LDH activity, indicating the mouse MIRI model was successfully established. MiR-217 was up-regulated in MIRI mice and hypoxia/reoxygenation-treated H9C2 cells. MiR-217 knockdown alleviated the MIRI in MIRI mouse model, and also attenuated the myocardial hypoxia/reoxygenation injury in H9C2 cells. Moreover, dual specificity protein phosphatase 14 (DUSP14) was proved to be a target of miR-217. Besides, further study indicated that inhibition of miR-217 protected against MIRI through inactivating NF-κB and MAPK pathways via targeting DUSP14. MiR-217 inhibition protected against MIRI through inactivating NF-κB and MAPK pathways by targeting DUSP14. This study may provide valuable diagnostic and factors and therapeutic agents for MIRI.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Monoclonal Anti-NF-κB antibody produced in mouse, clone NF-12, ascites fluid
Sigma-Aldrich
Anti-GAPDH antibody produced in rabbit, affinity isolated antibody
Sigma-Aldrich
Anti-phospho-ERK1/2 (pThr202/Tyr204) antibody produced in rabbit, affinity isolated antibody
Sigma-Aldrich
Anti-phospho-SAPK/JNK (pThr183) antibody produced in rabbit, affinity isolated antibody
Sigma-Aldrich
MONOCLONAL ANTI-ERK1/2 antibody produced in mouse, clone 784CT7.6.3, IgG fraction of antiserum, buffered aqueous solution
Sigma-Aldrich
Anti-phospho-NF-κB p100 (pSer872) antibody produced in rabbit, affinity isolated antibody
Sigma-Aldrich
Anti-phospho-p38 MAPK (pTyr322) antibody produced in rabbit, affinity isolated antibody
Sigma-Aldrich
Anti-JNK antibody, Mouse monoclonal, clone 1C2, purified from hybridoma cell culture
Sigma-Aldrich
Anti-DUSP14 antibody produced in mouse, purified immunoglobulin, buffered aqueous solution
Sigma-Aldrich
Anti-p38 MAP Kinase, Activated (Diphosphorylated p38) antibody, Mouse monoclonal, clone P38-TY, purified from hybridoma cell culture, buffered aqueous solution